Abstract
Background
Soluble urokinase plasminogen activator receptor (suPAR) has been regarded as a permeability factor in proteinuria, though its role in primary nephrotic syndrome remains to be elucidated further.
Methods
Plasma samples and clinical information from 176 children with primary nephrotic syndrome were collected and concentrations of suPAR were measured. We evaluated the correlation between suPAR concentrations and clinical features, and the value of the plasma suPAR level in predicting steroid-resistant nephrotic syndrome (SRNS).
Results
There is a significant difference in plasma suPAR concentration between SRNS and steroid-sensitive nephrotic syndrome (SSNS) groups (3,744.1 ± 2,226.0 vs. 2,153.5 ± 1,167.0, p < 0.05). The area under the curve (AUC) was 0.80, with p < 0.001 for the receiver operating characteristic (ROC) curve analysis using suPAR to predict SRNS. The suspicious range for predicting SRNS was estimated to be 1,907.0 pg/ml to 3,043.5 pg/ml (χ2 = 14.775, p = 0.001).
Conclusions
From ROC curve analysis, we demonstrated the significance of the suPAR level in predicting SRNS with a high specificity but low sensitivity. However, the clinical value of suPAR to predict steroid resistance and guide therapy remains to be investigated further.
Similar content being viewed by others
References
Thunø M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball. Dis Markers 27:157–172
D’Alessio S, Blasi F (2009) The urokinase receptor as an entertainer of signal transduction. Front Biosci 14:4575–4587
Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11:23–36
Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P (2007) Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17:428–437
Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55–63
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960
Kumagai T, Mouawad F, Takano T (2012) Pathogenesis of common glomerular diseases—role of the podocyte cytoskeleton. Cell Health Cytoskelet 2012:103–118
Zhang B, Xie S, Shi W, Yang Y (2012) Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 27:1746–1755
Zhang B, Shi W, Ma J, Sloan A, Faul C, Wei C, Reiser J, Yang Y, Liu S, Wang W (2012) The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med 90:1407–1420
Cheng CC, Lee YF, Lan JL, Wu MJ, Hsieh TY, Lin NN, Wang JM, Chiu YT (2013) Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model. Lupus 22:554–561
Sever S, Trachtman H, Wei C, Reiser J (2013) Is there clinical value in measuring suPAR levels in FSGS? Clin J Am Soc Nephrol 8:1273–1275
Naesens M, Meijers B, Sprangers B (2013) suPAR and FSGS: the gap between bench and bedside. Transplantation 96:368–369
Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C, Cortes DO, Grazulyte D, Gottin L, Vincent JL (2013) Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 29:144–149
Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868–1876
Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35:337–342
Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J (2004) Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 26:207–211
Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6:686–692
Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, Ikeda K, Yanase T, Fujimi S (1998) Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. Clin Nephrol 49:1–8
Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776
Wong W (2007) Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after 12-month follow-up: results of a 3-year national surveillance study. J Paediatr Child Health 43:337–341
Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, van Damme-Lombaerts R, Palcoux J-B, Cachat F, Lavocat M-P, Bourdat-Michel G, Nobili F, Cochat P (2009) Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 24:1525–1532
Wang W, Xia Y, Mao J, Chen Y, Wang D, Shen H, Fu H, Du L, Liu A (2012) Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 27:2073–2079
Yao SH, Mao JH, Xia YH, Wang DY, Chen YF, Fang CQ, Liu AM, Du LZ (2011) Clinical application of tacrolimus with low-dose prednisone in 21 children with steroid-resistant nephrotic syndrome. Chin J Pediatr 49:825–828
Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PodoNet CFCS (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23:2051–2059
Kemper MJ, Wei C, Reiser J (2013) Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 61:9
Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH (2013) Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84:366–372
Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H (2013) Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96:394–399
Meijers B, Maas RJH, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JKJ, Dietrich R, Storr M, Wetzels JFM, Evenepoel P, Kuypers D (2014) The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85:636–640
Bock ME, Price HE, Gallon L, Langman CB (2013) Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 8:1304–1311
Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A (2014) Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85:649–658
Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto K, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S (2014) A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int 85:641–648
Maas RJ, Deegens JK, Wetzels JF (2013) Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 28:1041–1048
Acknowledgments
This project was supported by the National Natural Science Foundation of China (Grant Nos. 81270792, 81070561 and 81170664), the State “1025” Science and Technology Support Projects (2012BAI03B02), the Research Fund for the Doctoral Program of Higher Education of China (20120101110018), the Zhejiang Provincial Healthy Science Foundation of China (WKJ2010-2-014, 2012KYA119, 2014KYA123), the Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents and the Zhejiang Provincial Natural Science Foundation of China (LY12H050037). We thank the patients and their family members for participating in this study.
Disclosure statement
No competing interests declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peng, Z., Mao, J., Chen, X. et al. Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol 30, 301–307 (2015). https://doi.org/10.1007/s00467-014-2892-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-014-2892-6